Revance Therapeutics announced two poster presentations showcasing the efficacy and performance of DAXXIFY® for the treatment of cervical dystonia.
• Analysis of the ASPEN-1 and ASPEN-OLS trials revealed that approximately 50% of peak efficacy remained at the time of patients’ early retreatment requests.
• In the ASPEN-OLS long-term follow-up study, 60% of retreatments occurred at or after 16 weeks.
These findings suggest that DAXXIFY’s long-acting symptom control allows for individualized treatment intervals, providing sustained symptom relief and reducing the “symptom rollercoaster” experienced by many cervical dystonia patients.
A second poster examined DAXXIFY’s unique formulation and the role of its engineered peptide (RTP004). Data showed that RTP004:
• Enhances binding of neurotoxin to cell membranes, facilitating toxin entry into neurons.
• Increases SNAP-25 cleavage in neurons in a dose-dependent manner.
• Localizes within the injected muscle.
This formulation allows for a smaller amount of neurotoxin to be administered while maintaining long-lasting efficacy, contributing to DAXXIFY’s strong safety and differentiated performance profile.
Dr. David Hollander, Chief Medical Officer at Revance, highlighted the potential of DAXXIFY’s long-lasting effects to tailor treatment intervals to individual patient needs, ensuring sustained symptom control and reducing treatment burden.
Overall, the presented data reinforces the efficacy and customizable nature of DAXXIFY in managing cervical dystonia, empowering physicians to optimize treatment outcomes for their patients.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
